TABLE 1.
Baseline patient characteristics at diagnosis.
| Total n = 183 | |
|---|---|
| Age at diagnosis (years) | |
| Median (IQR) | 63.0 (56.0–67.0) |
| ECOG at diagnosis: n (%) | |
| 0–1 | 144 (82.8) |
| ≥2 | 30 (17.2) |
| WBC at diagnosis (×109/L) | |
| Median (IQR) | 4.1 (2.0–12.8) |
| AML status: n (%) | |
| De novo | 103 (56.3) |
| Secondary AML | 80 (43.7) |
| Cytogenetic risk: n (%) | |
| Favorable | 0 (0.0) |
| Intermediate | 60 (32.8) |
| Adverse | 123 (67.2) |
| ELN 2010 prognosis: n (%) | |
| Favorable | 3 (1.7) |
| Intermediate‐I/II | 48 (27.8) |
| Adverse | 122 (70.5) |
| FLT3‐ITD: n (%) | |
| Mutation | 9 (9.7) |
| No mutation | 84 (90.3) |
| NPM1: n (%) | |
| Mutation | 6 (7.1) |
| No mutation | 78 (92.9) |
| CEBPA: n (%) | |
| Mutation | 3 (5.7) |
| No mutation | 50 (94.3) |
Abbreviations: IQR, interquartile range; WBC, white blood cells; ECOG, Eastern Cooperative Oncology Group; AML, acute myeloid leukemia; ELN, European LeukemiaNet.